For Oncologists

Understanding Treatment
Response Heterogeneity

Intra-patient heterogeneity is nearly universal in cancer.1. Having as few at 9% of lesions not responding to therapy can result in significantly worse outcomes.2,3

SUVhetero is an imaging metric of intra-patient heterogeneity. Change in SUVhetero was the most significant predictor of time to PSA progression (hazard ratio [HR], 3.88; 95% CI, 1.24 to 12.1) and time to treatment discontinuation (HR, 4.21; 95% CI, 1.28 to 13.8) in a study of men with progressive metastatic castration-resistant prostate cancer (mCRPC).3

1. Meacham et al, Nature, 2013; 2. Harmon et al., J Clin Oncol 2017, including unpublished supplemental data analysis; 3. Kyriakopoulos et al, J Clin Oncol 2020.

TRAQinform IQ Technology

TRAQinform IQ is AI-driven software that provides novel information about treatment response.
Oncologists use this technology to more precisely adjust therapies and optimize clinical outcomes.

TRAQinform IQ uses serial radiographic images (e.g., PET, CT)

Images are uploaded via the cloud to AIQ solutions (HIPAA compliant)

AI-driven software provides novel, quantitative and spatial information about each region of interest

A comprehensive report is generated and delivered to the oncologist

Oncologists can use the information to tailor treatment regimens and optimize outcomes

Clinical Application: Making Confident Treatment Decisions

TRAQinform IQ works with all therapy types including immunotherapy, chemotherapy,
radiation therapy, targeted therapy and hormone therapy.

Find Out More…

Metric Definition Clinical Indication
ROI Region of Interest Volume of potential interest based on imaging analysis
SUV Standardized Uptake Value Quantification of measured radioactivity
SUVtotal (TLG equivalent) SUVmean x ROI Volume calculated at both the ROI and patient level Global indication of disease burden
SUVhetero Standard Deviation of ROI SUVmean Global indication of ROI heterogeneity
Powered by
Australian Privacy Policy AIQ's software has been cleared for clinical use under 510(k) K173444. For details, including the applicable Indications for Use, see: